Shots:

• The P-I/II trial evaluates INO-5401 + INO-9012 in combination with Libtayo in 32 patients with an unmethylated MGMT (cohort A) & 20 in MGMT methylated (cohort B) with GBM
• The results showed that m-OS in patients with unmethylated MGMT (cohort A) was 17.9mos., the combination therapy was found to be tolerable & immunogenic administered with RT/TMZ & also elicited Ag-specific T cells that may infiltrate GBM tumors., 55% of MGMT methylated patients (cohort B) remain alive at a median of 32.5mos.
• Additionally, 23% & 28% reduction in risk of death @18mos. The gene expression levels of INO-5401 Ag & immune cell markers from pre-treatment tumor tissues were similar b/w alive & deceased groups in a post-hoc exploratory study

Ref: Inovio | Image: Inovio